Anesthesia Pharmacology Chapter 25: Pulmonary Pharmacology Practice Questions

With respect to the immune system, a central aspect of allergic asthma is increased IgE.
1. True
2. False
Inhibition of IgE binding to IgE receptors is blocked by omalizumab (Xolair) on which one(s) of the following?
1. T lymphocytes
2. Macrophages
3. Mast cells
4. A & B
5. B & C
6. A & C
7. A, B & C
Concerning omalizumab (Xolair):
1. This agent is used in treating mainly patients with mild asthma
2. This agent is used in treating mainly patients with moderate asthma symptoms.
3. This agent is mainly used for treating severe asthmatic patients.
Omalizumab (Xolair):
1. This agent is an antibody.
2. Omalizumab's route of administration is by subcutaneous injection.
3. Omalizumab and does not change the requirement for oral or inhaled corticosteroids given that the agent works by different mechanisms.
4. A & B
5. B & C
6. A & C
7. A, B & C
Omalizumab decreases asthma exacerbation along with reducing dosages both for oral and inhaled corticosteroids.
1. True
2. False
Anaphylactic reactions can occur following omalizumab administration.
1. True
2. False
Omalizumab administration decreases the magnitude of late as well as early bronchospasm response subsequent to antigen challenge
1. True
2. False
Most important omalizumab clinical effect(s):
1. Reduction in frequency of asthma exacerbations
2. Reduction of severity of asthma exacerbations
3. Both
4. Neither
Omalizumab clinical use/uces:
1. Effective for treating chronic, recurrent urticaria (Approved indication)
2. Effective in peanut allergy
3. Both
4. Neither
Likely appropriate for treatment of eosinophilic asthma:
1. Mepolizumab (Nucala)
2. Reslizumab (Cinqair)
3. Both
4. Neither
This drug, monoclonal antibody, targets the IL-5 receptor.
1. Mepolizumab (Nucala)
2. Benralizumab (Fasenra)
3. Reslizumab (Cinqair)
May be associated with herpes zoster reactivation:
1. Mepolizumab
2. Reslizumab
3. Omalizumab
Small risk of anaphylaxis following administration of this/these agent(s):
1. Reslizumab
2. Omalizumab
3. Both
4. Neither